Compare Orchid Chemicals with ASTRAZENECA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ORCHID PHARMA LTD vs ASTRAZENECA PHARMA - Comparison Results

ORCHID PHARMA LTD     Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ORCHID PHARMA LTD ASTRAZENECA PHARMA ORCHID PHARMA LTD/
ASTRAZENECA PHARMA
 
P/E (TTM) x -0.5 94.6 - View Chart
P/BV x 0.1 26.6 0.4% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 ORCHID PHARMA LTD   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    ORCHID PHARMA LTD
Sep-13
ASTRAZENECA PHARMA
Mar-18
ORCHID PHARMA LTD/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs1941,278 15.2%   
Low Rs35883 4.0%   
Sales per share (Unadj.) Rs276.5228.4 121.0%  
Earnings per share (Unadj.) Rs-79.210.4 -764.3%  
Cash flow per share (Unadj.) Rs-43.516.3 -267.2%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs53.998.8 54.6%  
Shares outstanding (eoy) m70.4525.00 281.8%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x0.44.7 8.8%   
Avg P/E ratio x-1.4104.2 -1.4%  
P/CF ratio (eoy) x-2.666.4 -4.0%  
Price / Book Value ratio x2.110.9 19.4%  
Dividend payout %00-   
Avg Mkt Cap Rs m8,06727,008 29.9%   
No. of employees `0002.81.4 206.5%   
Total wages/salary Rs m2,5271,535 164.6%   
Avg. sales/employee Rs Th6,956.14,210.9 165.2%   
Avg. wages/employee Rs Th902.51,132.2 79.7%   
Avg. net profit/employee Rs Th-1,993.0191.1 -1,043.0%   
INCOME DATA
Net Sales Rs m19,4775,710 341.1%  
Other income Rs m407123 332.4%   
Total revenues Rs m19,8845,833 340.9%   
Gross profit Rs m1,103463 238.2%  
Depreciation Rs m2,519147 1,709.1%   
Interest Rs m5,2270-   
Profit before tax Rs m-6,236438 -1,423.8%   
Minority Interest Rs m200-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m5110-   
Tax Rs m-125179 -70.0%   
Profit after tax Rs m-5,580259 -2,153.7%  
Gross profit margin %5.78.1 69.8%  
Effective tax rate %2.040.8 4.9%   
Net profit margin %-28.74.5 -631.4%  
BALANCE SHEET DATA
Current assets Rs m11,0143,209 343.2%   
Current liabilities Rs m32,0602,070 1,549.2%   
Net working cap to sales %-108.120.0 -541.4%  
Current ratio x0.31.6 22.2%  
Inventory Days Days9572 131.2%  
Debtors Days Days3435 96.1%  
Net fixed assets Rs m29,440790 3,725.2%   
Share capital Rs m70550 1,409.0%   
"Free" reserves Rs m2,0432,419 84.4%   
Net worth Rs m3,8002,469 153.9%   
Long term debt Rs m9,0180-   
Total assets Rs m46,5104,605 1,009.9%  
Interest coverage x-0.2NM-  
Debt to equity ratio x2.40-  
Sales to assets ratio x0.41.2 33.8%   
Return on assets %-0.85.6 -13.5%  
Return on equity %-146.910.5 -1,399.6%  
Return on capital %-3.717.7 -21.1%  
Exports to sales %37.90-   
Imports to sales %22.60-   
Exports (fob) Rs m7,378NA-   
Imports (cif) Rs m4,406NA-   
Fx inflow Rs m7,513300 2,508.2%   
Fx outflow Rs m5,6492,015 280.3%   
Net fx Rs m1,865-1,715 -108.7%   
CASH FLOW
From Operations Rs m1,68288 1,913.2%  
From Investments Rs m-9,860-94 10,534.6%  
From Financial Activity Rs m6,644NA-  
Net Cashflow Rs m-1,535-6 26,929.8%  

Share Holding

Indian Promoters % 32.3 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 4.6 0.3 1,533.3%  
FIIs % 3.3 15.7 21.0%  
ADR/GDR % 4.6 0.0 -  
Free float % 55.3 9.1 607.7%  
Shareholders   84,811 12,856 659.7%  
Pledged promoter(s) holding % 54.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ORCHID PHARMA LTD With:   IPCA LABS  SANOFI INDIA  ALEMBIC PHARMA  PROCTER & GAMBLE HEALTH  NOVARTIS  

Compare ORCHID PHARMA LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 72 Points Lower; Capital Goods and Auto Stocks Witness Selling(Closing)

India share markets witnessed selling pressure during closing hours and ended their day marginally lower.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Mar 29, 2019 | Updated on Mar 29, 2019

Here's an analysis of the annual report of ASTRAZENECA PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ASTRAZENECA PHARMA. Also includes updates on the valuation of ASTRAZENECA PHARMA.

ASTRAZENECA PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 381.0% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 291 m (up 381.0% YoY). Sales on the other hand came in at Rs 2 bn (up 67.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ORCHID PHARMA LTD Announces Quarterly Results (2QFY19); Net Profit Up 67.1% (Quarterly Result Update)

Jan 31, 2019 | Updated on Jan 31, 2019

For the quarter ended September 2018, ORCHID PHARMA LTD has posted a net profit of Rs 231 m (up 67.1% YoY). Sales on the other hand came in at Rs 1 bn (down 31.9% YoY). Read on for a complete analysis of ORCHID PHARMA LTD's quarterly results.

More Views on News

Most Popular

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

These 10 Days Are Crucial for Getting Rich in the Smallcap Rebound(Profit Hunter)

Nov 5, 2019

How to avoid the most common investing mistake and make the most of the smallcap rebound.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

A Trade that Could Generate Profits for Decades

Nov 14, 2019

India's #1 trader is back on the Investor Hour. Vijay Bhambwani talks to us about his super-profitable trading system and shares with us his #1 long term trade. Listen in...

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ORCHID PHARMA LTD SHARE PRICE


Jul 24, 2019 (Close)

TRACK ORCHID PHARMA LTD

  • Track your investment in ORCHID PHARMA LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ORCHID PHARMA LTD

ORCHID PHARMA LTD 5-YR ANALYSIS

COMPARE ORCHID PHARMA LTD WITH

MARKET STATS